Trevena Inc (TRVN)
1.69
-0.06
(-3.43%)
USD |
OTCM |
Nov 04, 16:00
Trevena Revenue (Quarterly): 0.325M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 0.325M |
March 31, 2024 | 0.02M |
December 31, 2023 | -0.082M |
September 30, 2023 | 0.18M |
June 30, 2023 | 3.021M |
March 31, 2023 | 0.006M |
December 31, 2022 | |
September 30, 2022 | -0.438M |
June 30, 2022 | |
March 31, 2022 | 0.02M |
December 31, 2021 | -0.001M |
September 30, 2021 | 0.181M |
June 30, 2021 | 0.178M |
March 31, 2021 | 0.209M |
December 31, 2020 | 0.069M |
September 30, 2020 | 3.00M |
June 30, 2020 | |
March 31, 2020 | |
December 31, 2019 | 0.031M |
September 30, 2019 | |
June 30, 2019 | |
March 31, 2019 | |
December 31, 2018 | 0.232M |
September 30, 2018 | 3.00M |
Date | Value |
---|---|
June 30, 2018 | 2.50M |
March 31, 2018 | |
December 31, 2017 | |
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | 1.875M |
March 31, 2016 | 1.875M |
December 31, 2015 | 1.875M |
September 30, 2015 | 1.875M |
June 30, 2015 | 1.875M |
March 31, 2015 | 0.625M |
December 31, 2014 | |
September 30, 2014 | |
June 30, 2014 | |
March 31, 2014 | |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | 0.0938M |
March 31, 2013 | 0.0412M |
December 31, 2012 | 0.2526M |
September 30, 2012 | 0.1474M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-0.438M
Minimum
Sep 2022
3.021M
Maximum
Jun 2023
0.4479M
Average
0.069M
Median
Dec 2020
Revenue (Quarterly) Benchmarks
Pfizer Inc | 17.70B |
United Therapeutics Corp | 748.90M |
Syndax Pharmaceuticals Inc | 3.50M |
Arcus Biosciences Inc | 39.00M |
NovaBay Pharmaceuticals Inc | 2.40M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -4.891M |
Total Expenses (Quarterly) | 6.828M |
EPS Diluted (Quarterly) | -5.75 |
Enterprise Value | 16.60M |
Gross Profit Margin (Quarterly) | 68.31% |
Profit Margin (Quarterly) | -1.50K% |
Earnings Yield | -3.39K% |
Normalized Earnings Yield | -3705.22 |